Clinical trial
Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
NCT02213913 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
- Lead sponsor
- University of Chicago
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 29, 2014
- Completion date
- October 29, 2024
- Enrollment
- 55 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
adult grade iii lymphomatoid granulomatosis, b-cell chronic lymphocytic leukemia, contiguous stage ii adult diffuse large cell lymphoma, contiguous stage ii adult diffuse mixed cell lymphoma, contiguous stage ii adult diffuse small cleaved cell lymphoma, contiguous stage ii adult immunoblastic large cell lymphoma, contiguous stage ii grade 1 follicular lymphoma, contiguous stage ii grade 2 follicular lymphoma, contiguous stage ii grade 3 follicular lymphoma, contiguous stage ii mantle cell lymphoma, contiguous stage ii marginal zone lymphoma, contiguous stage ii small lymphocytic lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncontiguous stage ii adult diffuse large cell lymphoma, noncontiguous stage ii adult diffuse mixed cell lymphoma, noncontiguous stage ii adult diffuse small cleaved cell lymphoma, noncontiguous stage ii adult immunoblastic large cell lymphoma, noncontiguous stage ii grade 1 follicular lymphoma, noncontiguous stage ii grade 2 follicular lymphoma, noncontiguous stage ii grade 3 follicular lymphoma, noncontiguous stage ii mantle cell lymphoma, noncontiguous stage ii marginal zone lymphoma, noncontiguous stage ii small lymphocytic lymphoma, progressive hairy cell leukemia, initial treatment, small intestine lymphoma, splenic marginal zone lymphoma, stage 0 chronic lymphocytic leukemia, stage i adult diffuse large cell lymphoma, stage i adult diffuse mixed cell lymphoma, stage i adult diffuse small cleaved cell lymphoma, stage i adult hodgkin lymphoma, stage i adult immunoblastic large cell lymphoma, stage i chronic lymphocytic leukemia, stage i grade 1 follicular lymphoma, stage i grade 2 follicular lymphoma, stage i grade 3 follicular lymphoma, stage i mantle cell lymphoma, stage i marginal zone lymphoma, stage i small lymphocytic lymphoma, stage ii adult hodgkin lymphoma, stage ii chronic lymphocytic leukemia, stage ii small lymphocytic lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii chronic lymphocytic leukemia, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii small lymphocytic lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv chronic lymphocytic leukemia, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv small lymphocytic lymphoma, testicular lymphoma, untreated hairy cell leukemia, waldenström macroglobulinemia